Phaseline

Companies › Xfibra

Xfibra: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XFB19
C/EBPβ Thr266 phosphorylation inhibitor targeting NLRP3 inflammasome activation
CEBPBPhase 1Focus of the Study: Safety of XFB19Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05361733XFB19Phase 1Focus of the Study: Safety of XFB19OtherDec 2026

Targets

CEBPB (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.